Ipilimumab Yields ‘Limited Effect’ in Refractory Kidney Cancer Subtype
Cancer Network,
In an interview with CancerNetwork® during the 2023 Genitourinary Cancers Symposium, Tian Zhang, MD, MHS, discussed how…
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).
Overview of attention for article published in Journal of Clinical Oncology, October 2020
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (95th percentile)
-
Good Attention Score compared to outputs of the same age and source (79th percentile)
Readers on
- mendeley
- 58 Mendeley
